WuXi XDC Cayman Inc.
PublicWuXi XDC Cayman Inc. is now publicly traded
The data on this page reflects WuXi XDC Cayman Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Nov 17, 2023
Last Round
Follow-on Offering
Sep 3, 2025
Total Funding Raised
$1.02B
Company Overview
WuXi XDC Cayman Inc. is a publicly traded Contract Research, Development, and Manufacturing Organization (CRDMO) that specializes in bioconjugates, with a primary focus on Antibody-Drug Conjugates (ADCs). Spun off from WuXi Biologics, the company offers a comprehensive, single-source platform of services from discovery and process development to GMP manufacturing of bioconjugates, monoclonal antibody intermediates, and payload-linkers. The company operates globally with facilities in China (Wuxi, Shanghai, Changzhou) and is expanding with a new site in Singapore to implement a "global dual sourcing" strategy. WuXi XDC was established as a joint venture in 2021 and went public on the Hong Kong Stock Exchange (stock code: 2268.HK) in November 2023.
AI Layer
Non-AI
Keywords
WuXi XDC Cayman Inc. Comparables
Compare WuXi XDC Cayman Inc. with similar companies based on industry and business-model similarity.
WuXi XDC Cayman Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Sep 3, 2025 | ||||
| IPO | Nov 17, 2023 | ||||
| Corporate Funding | May 14, 2021 |
WuXi XDC Cayman Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Credit Suisse Asset Management | IPO |
| WuXi STA | Corporate Funding |
| General Atlantic | IPO |
| Qatar Investment Authority | IPO |
WuXi XDC Cayman Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |